Thu 08/18/2022 12:45 PM
Aenova’s long-running production issues mounted in June, impacting output. That resulted in a 57% year-over-year drop in reported EBITDA, sending the loans of the German pharma contract development and manufacturing organization, or CDMO, down to 87, offer only, from around 91/92 previously, sources told Reorg.
Net sales reached €60.2 million in June, missing €64.3 million budgeted and slightly down on €60.8 million the same month last year. Adjusted EBITDA came in at €4.3...
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2024 Reorg Research, Inc. All rights reserved.